Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Doretti

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Therapeutic Advances in Neurological Disorders|December 25, 2025
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)Gloria Vaghi, Luigi Francesco Iannone, Michele Corrado, et al.
Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Therapeutic Advances in Neurological Disorders|December 25, 2025
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)Gloria Vaghi, Luigi Francesco Iannone, Michele Corrado, et al.
Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Pageof 7